Research Paper Volume 11, Issue 9 pp 2874—2888
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Figure 3. Left. Waterfall plots showing the log2 fold chance of circulating α-KG and correlation with treatment outcomes. Right. Violin plots depicting the log2 fold chance of circulating α-KG in each treatment arm categorized by treatment outcomes. (pCR: pathological complete response; QT: chemotherapy; Tzb: trastuzumab; MET: metformin; p-values by Wilcoxon signed-ranked test).